Keyword: Allergy Therapeutics
Allergy Therapeutics saw its stock down 40% in early trading in London after its birch pollen drug failed to move the needle in a key phase 3 trial.
A phase 2 trial of Allergy Therapeutics’ grass pollen candidate met its primary endpoint of showing a dose-response relationship.
Lundbeck chief Schultz will lead Teva, former CDC director Frieden leads a new health project, Roivant named Eisai exec Waxman as general counsel.
Allergy Therapeutics failed to determine the recommended dose in a Phase II trial, forcing it to run another study and delaying its advance.